Recent Publications
2011
Boss DS, Glen H, Beijnen JH, de Jong D, Wanders J, Evans TR, Schellens JH (2011). Serum beta-HCG and CA-125 as tumor markers in a patient with osteosarcoma: case report. Tumori 97, 109-14.
Venugopal B, Evans TR (2011). Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr Med Chem. 18, 1658-71.
2010
Ahmad I, Morton JP, Singh LB, Radulescu SM,
Ridgway RA, Patel S, Woodgett J, Winton DJ, Taketo
MM, Wu XR, Leung HY, Sansom OJ (2010).
beta-Catenin activation synergizes with PTEN loss
to cause bladder cancer formation. Oncogene 30, 178-89.
Ashton GH, Morton JP, Myant K, Phesse TJ,
Ridgway RA, Marsh V, Wilkins JA, Athineos D,
Muncan V, Kemp R, Neufeld K, Clevers H, Brunton
V, Winton DJ, Wang X, Sears RC, Clarke AR, Frame
MC, Sansom OJ (2010). Focal adhesion kinase is required for intestinal
regeneration and tumorigenesis downstream of
Wnt/c-Myc signaling. Dev Cell 19, 259-69.
Doyle B, Morton JP, Delaney DW, Ridgway RA,
Wilkins JA, Sansom OJ (2010).
p53 mutation and loss have different effects on
tumourigenesis in a novel mouse model of
pleomorphic rhabdomyosarcoma. J Pathol. 222,
129-37.
Lolkema MP, Arkenau H-T, Harrington K, Roxburgh
P, Morrison R, Roulstone V, Coffey M, Mettinger K,
Gill G, Evans TRJ, de Bono JS (2010).
A phase-I study of the combination of intravenous
reovirus type 3 Dearing and gemcitabine in patients
with advanced cancer. Clin Cancer Res. 17, 581-8.
Mansi JL, Yellowlees A, Lipscombe J, Earl HM,
Cameron DA, Coleman RE, Perren T, Gallagher CJ,
Quigley M, Crown J, Jones AL, Highley M, Leonard
RC, Evans TR (2010).
Five-year outcome for women randomised in a
phase III trial comparing doxorubicin and
cyclophosphamide with doxorubicin and docetaxel
as primary medical therapy in early breast cancer:
an Anglo-Celtic Cooperative Oncology Group study.
Breast Cancer Res Treat. 122, 787-94.
Mitchell CL, O'Connor JP, Roberts C, Watson Y,
Jackson A, Cheung S, Evans J, Spicer J, Harris A,
Kelly C, Rudman S, Middleton M, Fielding A, Tessier
J, Young H, Parker GJ, Jayson GC (2010).
A two-part Phase II study of cediranib in patients
with advanced solid tumours: the effect of food on
single-dose pharmacokinetics and an evaluation of
safety, efficacy and imaging pharmacodynamics.
Cancer Chemother Pharmacol. 2010 Dec 1. [Epub ahead of print]
Morton JP, Jamieson NB, Karim SA, Athineos D,
Ridgway RA, Nixon C, McKay CJ, Carter R,
Brunton VG, Frame MC, Ashworth A, Oien KA,
Evans TR, Sansom OJ (2010).
LKB1 haploinsufficiency cooperates with Kras to
promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology
139, 586-97.
Morton JP, Karim SA, Graham K, Timpson P,
Jamieson N, Athineos D, Doyle B, McKay C, Heung
MY, Oien KA, Frame MC, Evans TR, Sansom OJ,
Brunton VG (2010).
Dasatinib inhibits the development of metastases
in a mouse model of pancreatic ductal
adenocarcinoma. Gastroenterology 139,
292-303.
Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B,
Jamieson NB, Oien KA, Lowy AM, Brunton VG, Frame MC, Evans TRJ,
Sansom OJ (2010). Mutant p53 drives metastasis and overcomes growth
arrest/senescence in pancreatic cancer. Proc Natl Acad Sci USA 107,
246-51.
Steele NL, Plumb JA, Vidal L, Tjornelund J,
Knoblauch P, Buhl-Jensen P, Molife R, Brown R, de
Bono JS, Evans TR (2010).
Pharmacokinetic and pharmacodynamic properties
of an oral formulation of the histone deacetylase
inhibitor Belinostat (PXD101). Cancer Chemother
Pharmacol. 67, 1273-9.
Brown J, Evans TRJ (2010).
In: Medical Radiology - New Concepts in Diagnosis
and Therapy of Pancreatic Adenocarcinoma (ed:
Laghi A) pp137-46. Springer, Heidelberg.
Evans TRJ (2010).
Upper Gastrointestinal Cancer. In: Oxford Handbook
of Oncology, 3rd Edition (eds: Cassidy J, Bissett D,
Spence RAJ, Payne M) pp333-53. Oxford University Press, Oxford.
Morton JP, Sansom OJ, Evans TRJ (2010).
Pancreatic Cancer Therapy – Lessons from Mouse
Models. Gastrointestinal Cancer Abstracts 29,
2-7.
2009
Demetri GD, Lo Russo P, Macpherson IR, Wang D, Morgan JA, Brunton VG, Paliwal P, Agrawal S, Voi M, Evans TR (2009). Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors. Clin Cancer Res. 15, 6232-40.
Graham JS, Falk S, Samuel LM, Cendros JM, Evans TRJ (2009). A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy. Cancer Chemotherapy & Pharmacology 63, 945-52.
Scott LC, Yao JC, Benson AB, 3rd,Thomas AL, Falk S, Mena RR, Picus J,Wright J, Mulcahy MF, Ajani JA, Evans TRJ (2009). A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemotherapy & Pharmacology 63, 363-70.
Venugopal B, Evans TR (2009). Coexistent malignant melanoma and renal cell carcinoma. Tumori 95, 518-20.
Braidwood L, Dunn PD, Hardy S, Evans TR, Brown SM (2009). Antitumor Activity of a Selectively Replication Competent Herpes Simplex Virus (HSV) with Enzyme Prodrug Therapy. Anticancer Res. 29, 2159-66.
Koutras AK, Giannopoulou E, Antonacopoulou A, Evans TRJ, Kalofonos HP (2009). Antiproliferative effect of exemestane in lung cancer cells. Molecular Cancer 8, 109.
Scott LC, Evans TR, Cassidy J, Harden S, Paul J, Ullah R, O'Brien V, Brown R (2009). Cytokeratin 18 in plasma of patients with
gastrointestinal adenocarcinoma as a biomarker of tumour response. Br J Cancer 101, 410-7.
Harrington J, Evans TRJ (2009). Recent Advances in the Systemic Therapy of Cancer. Journal of the Royal College of Physicians of Edinburgh 39, 134-7.
Macpherson IRJ, Evans TRJ (2009). New approaches in the management of advanced breast cancer – role of combination treatment with
liposomal doxorubicin. Breast Cancer – Targets and Therapy 1, 1-18.
2008
Morton JP, Klimstra DS, Mongeau ME, Lewis BC (2008). Trp53 deletion stimulates the formation of metastatic pancreatic tumors. Am J Path. 172, 1081-7.
Plummer R, Jones R, Middleton M,Wilson R, Evans J, Olsen A, Curtin N, Boddy A, McHugh P, Newell D, Harris A, Johnston P, Steinfeldt H, Dewji R,Wang D, Robson L, Calvert H (2008). Phase I study of the poly(ADP-Ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumours. Clin Cancer Res. 23, 7917-23.
Sarker D, Molife R, Evans TRJ, Hardie M, Marriott C, Butzberger-Zimmerli P, Morrison R, Fox JA, Heise C, Louie S,Aziz N, Garzon F, Michelson G, Judson IR, Jadayel D, Braendle E, de Bono JS (2008). A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res. 14, 2075-81.
Steele NL, Plumb JA,Vidal L,Tjornelund J, Knoblauch P, Rasmussen A, Ooi CE, Buhl-Jensen P, Brown R, Evans TRJ, DeBono JS (2008). A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res. 14, 804-10.
Evans J, Chitnis MM,Talbot DC (2008). Principles of chemotherapy and drug development. In P. Price, K. Sikora and T. Illidge, ed. Treatment of cancer. London: Hodder Arnold 2008; 75-111
Koutras AK, Mastronikolis NS, Evans TRJ, Papadeas ES, Makatsoris T, Kalofonos HP (2008). Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer. Acta Oncologica 47, 1171-73.
Koutras AK, Evans TRJ (2008). The epidermal growth factor receptor family in breast cancer. Onco Targets & Therapy 1, 5-19.
Oien KA, Evans TRJ (2008). Raising the profile of cancer of unknown primary. J Clin Oncol. 26, 4373-75.
Roxburgh P, Evans TRJ (2008). Systemic therapy of hepatocellular carcinoma: Are we making progress? Advances in Therapy 25, 1089-104.
Holmes WM, Maclellan S, Condon B, Dufes C, Evans TRJ, Uchegbu IF, Schätzlein AG (2008). High-resolution 3D isotropic MR imaging of mouse flank tumours obtained in vivo with solenoid RF micro-coil. Physics in Medicine & Biology 53, 505-13.
Jones RJ, Hawkins RE, Eatock MM, Ferry DR, Eskens FA, Wilke H, Evans TRJ (2008). A phase II open label study of DHApaclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemotherapy & Pharmacology 61, 435-41.
Lindsay CR, Evans TRJ (2008). Targeting insulin growth factor receptors: a potential novel anti-cancer therapy. Biologics: Targets & Therapy 2, 855-64.
2007
Guo X, Evans TRJ, Somanath S, Armesilla AL, Darling JL, Schätzlein A, Cassidy J, Wang W (2007). In vitro evaluation of cancer-specific NF-kappaB-CEA enhancer-promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell lines. BJC 97, 745-54.
Macpherson IRJ, Jones RJ, Evans TRJ (2007). Clinical development of Src family kinase inhibitors in malignant melanoma. The Open Cancer J. 1, 9-20.
Øien KA, Dennis JL, Evans TRJ (2007). Metastatic adenocarcinoma of unknown origin. In N. Kirkham and N. A. Shepherd, ed. Progress in Pathology. Cambridge: Cambridge University Press; 135-62.
Øien KA, Stewart I, Evans TRJ (2007). Unknown primary. In M. R. Alison, ed. The Cancer Handbook. Chichester: John Wiley and Son; Chapter 61.
Current strategies in the development of new therapies for malignant disease are based on exploiting our increasing understanding of the molecular basis of cancer. 
Scientific Report 2010 Evans (
